Rating Change
JP Morgan analysts initiated coverage on KESTRA MEDICAL TECHNOLOGIES, LTD. (NASDAQ:KMTS) with a rating of Overweight on August 10, 2026.
new coverageNASDAQ:KMTS
JP Morgan Initiates Coverage on KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) with Overweight
JP Morgan analysts initiated coverage on KESTRA MEDICAL TECHNOLOGIES, LTD. (NASDAQ:KMTS) with a rating of Overweight on August 10, 2026.
At publication ·
What changed
KESTRA MEDICAL TECHNOLOGIES, LTD. (NASDAQ:KMTS) · new coverage
- Firm
- JP Morgan
- Rating
- Overweight
- Price at event
- $28.39
- Market capitalization
- $1.3B
At a glance
Key takeaways
- JP Morgan initiated coverage of Kestra Medical Technologies (KMTS) with an Overweight rating on August 10, 2026, while the stock trades at $28.39 with a $1.3B market capitalization.
Market Context
KESTRA MEDICAL TECHNOLOGIES, LTD. operates in the Healthcare sector. The stock currently trades at $28.39 with a market capitalization of $1.3B. The stock has gained 81.8% over the past 52 weeks.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for KESTRA MEDICAL TECHNOLOGIES, LTD.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for KESTRA MEDICAL TECHNOLOGIES, LTD.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | JP Morgan | Overweight | N/A |
| Jul 21, 2026 | Oppenheimer | Perform | N/A |
| Jul 15, 2026 | BTIG | Buy | N/A |
| Apr 09, 2026 | Goldman Sachs | Neutral | N/A |
| Apr 07, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KMTS Stock Page
Frequently Asked Questions
What does the Overweight rating mean for KMTS?
A rating of Overweight from JP Morgan reflects the analyst's outlook on KESTRA MEDICAL TECHNOLOGIES, LTD. (NASDAQ:KMTS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KMTS forecast page.